We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Acadia Pharmaceuticals has added novel pain programme to its portfolio with the acquisition of clinical-stage biotechnology company CerSci Therapeutics.
Acadia Pharmaceuticals' stock fell by more than 18% in premarket trading, triggering concerns about some deaths and adverse events in the company's Parkinson's drug, Nuplazid.